Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and emerging product lines. Management attributed the quarter’s strength to record-breaking test volumes—particularly for Signatera in oncology—and the successful launch of an enhanced Panorama prenatal test. CEO Steven Chapman highlighted increased adoption across tumor types and cited critical milestones, including FDA and Japanese regulatory approvals for Signatera, as key contributors to elevated clinical adoption. The quarter also saw a notable improvement in gross margins, which management linked to higher average selling prices and the scaling of recently launched products.

Is now the time to buy NTRA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Natera’s Q2 Earnings Call

• Puneet Souda (Leerink Partners) asked how sustainable the quarter’s Signatera growth and adoption are, and CEO Steven Chapman highlighted the cumulative effects of regulatory approvals, salesforce expansion, and strong data as drivers, but cautioned not to expect the same sequential growth each quarter.
• Dan Brennan (TD Cowen) questioned the ongoing potential for sequential pricing increases for Signatera, and CFO Michael Brophy explained that near-term ASP gains are likely to be modest, with larger step-ups dependent on future guideline and coverage decisions.
• David Westenberg (Piper Sandler) probed on competitive dynamics in MRD testing, and Chapman acknowledged competition but emphasized that market penetration is still low, leaving substantial growth potential for Natera despite new entrants.
• Noah Kava (Jefferies) sought color on share gains in women’s health, and Chapman pointed to recent product enhancements and technology investments as factors driving above-market growth and improved competitive positioning.
• Kallum Titchmarsh (Morgan Stanley) asked about the pace of Signatera’s Japan launch, and President Solomon Moshkevich expressed confidence in rapid awareness-building due to strong local guidelines and a combination of distribution and direct sales efforts.

Catalysts in Upcoming Quarters

In upcoming quarters, StockStory analysts will closely monitor (1) further progress in securing expanded payer coverage and guideline inclusions for Signatera, (2) the commercial rollout and reimbursement ramp in Japan, and (3) the pace of prospective clinical study readouts supporting expanded product indications. Additionally, we will track improvements in cost of goods sold and operational efficiency as new products scale.

Natera currently trades at $316.01, up from $265.38 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.